MedTrace Logo

Retrospective Survey of Safety of Fourth Dose Pentacel® in Children

NCT00772369 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3214

Last updated 2014-02-14

Study results available
· View outcomes & findings →

Summary

The purpose of this survey is to collect selected safety data.

Primary Objective:

To collect selected safety data at 6 months following the 4th dose of the Pentacel® series.

Conditions

  • Diphtheria
  • Pertussis
  • Haemophilus Infection
  • Tetanus
  • Polio

Sponsors & Collaborators

  • Sanofi Pasteur, a Sanofi Company

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Sanofi Pasteur Inc.

Eligibility

Min Age
12 Months
Max Age
24 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-09-30
Primary Completion
2004-04-30
Completion
2005-04-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00772369 on ClinicalTrials.gov